A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.
about
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitroA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroHuman immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primatesIncreased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3.Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodiesHyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.Small molecule targets Env for endoplasmic reticulum-associated protein degradation and inhibits human immunodeficiency virus type 1 propagation
P2860
Q24538755-33AA7F8E-F72B-4059-9E63-E1B256E4C7E3Q24563642-D65587A6-F9FE-42F4-A9A8-FD477EAD2074Q28728917-6F292815-BC7F-49D9-B74D-3C18AD486F58Q33933855-C0561DD8-F487-4091-92C7-F1B4EBEDF902Q34046807-C11428C8-4576-4152-8E34-BF65FD4403A7Q36046969-38B04F91-2401-4877-B64C-33423F991BC3Q36697629-C5ED168D-536C-477B-B9C0-D7B33084D201Q36781270-2260E17C-2D3D-44EC-B163-2DF255D69CA5Q36797252-59569CCA-27C7-4FCE-B119-33C19E69B7F8Q37284795-0FFF1909-6AB8-4BF7-8900-CFE71AE9A6F5Q37546827-6845B8BF-4009-4BE5-BEE8-4DCD95F42D73Q39579497-C7EB55A0-5562-463D-8C50-1F42E8BAAB2CQ42561408-30DDF91F-6E74-43B3-A98D-8CFA328E3DD6
P2860
A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
A monoclonal antibody to human ...... totoxicity and neutralization.
@ast
A monoclonal antibody to human ...... totoxicity and neutralization.
@en
type
label
A monoclonal antibody to human ...... totoxicity and neutralization.
@ast
A monoclonal antibody to human ...... totoxicity and neutralization.
@en
prefLabel
A monoclonal antibody to human ...... totoxicity and neutralization.
@ast
A monoclonal antibody to human ...... totoxicity and neutralization.
@en
P2093
P2860
P1433
P1476
A monoclonal antibody to human ...... totoxicity and neutralization.
@en
P2093
Akerblom L
Broliden PA
Ljunggren K
P2860
P304
P407
P577
1990-02-01T00:00:00Z